Observation of spin-exchange dynamics between itinerant and localized ¹⁷¹Yb atoms

We report on the observation of the spin-exchange dynamics of ¹⁷¹Yb atoms in the ground state ¹S₀ and in the metastable state ³P₀. We implement the mixed-dimensional two-orbital system using near-resonant and magic-wavelength optical lattices, where the ¹S₀ and ³P₀ atoms are itinerant in a one-dimensional tube and localized in three dimensions, respectively. By exploiting an optical Stern-Gerlach method, we observe the spin depolarization of the ¹S₀ atoms induced by the spin-exchange interaction with the ³P₀ atom. Our work could pave the way to the quantum simulation of the Kondo effect

Schemes for nondestructive quantum gas microscopy of single atoms in an optical lattice

We propose a quantum gas microscope for ultracold atoms that enables nondestructive atom detection, thus evading higher-band excitation and change of the internal degrees of freedom. We show that photon absorption of a probe beam cannot be ignored even in dispersive detection to obtain a signal-to-noise ratio greater than unity because of the shot noise of the probe beam under a standard measurement condition. The first scheme we consider for the nondestructive detection, applicable to an atom that has an electronic ground state without spin degrees of freedom, is to utilize a magic-wavelength condition of the optical lattice for the transition for probing. The second is based on the dispersive Faraday effect and squeezed quantum noise and is applicable to an atom with spins in the ground state. In this second scheme, a scanning microscope is adopted to exploit the squeezed state and reduce the effective losses. Application to ultracold ytterbium atoms is discussed

Anonymization server system for DICOM images

We have developed an anonymization system for DICOM images. It requires consent from the patient to use the DICOM images for research or education. However, providing the DICOM image to the other facilities is not safe because it contains a lot of personal data. Our system is a server that provides anonymization service of DICOM images for users in the facility. The distinctive features of the system are, input interface, flexible anonymization policy, and automatic body part identification. In the first feature, we can use the anonymization service on the existing DICOM workstations. In the second feature, we can select a best policy fitting for the Protection of personal data that is ruled by each medical facility. In the third feature, we can identify the body parts that are included in the input image set, even if the set lacks the body part tag in DICOM header. We installed the system for the first time to a hospital in December 2005. Currently, the system is working in other four facilities. In this paper we describe the system and how it works

Anti-tumor effects of interferon-beta cell therapy in murine model of melanoma

Purpose: Recombinant interferon beta (IFN-β) has been used for a treatment of cancers. However, the efficacy of recombinant IFN-β is limited because of its short half-life and side effects. To overcome these problems, we focused on the efficacy of cell-based therapy (cell therapy) using IFN-β-producing cells in the treatment of melanoma.Methods: IFN-β-producing therapeutic cells were constructed by gene transduction using retrovirus vector. Anti-tumor effects of the cell therapy were investigated by a murine melanoma model.Results: IFN-β cell therapy significantly suppressed the proliferation of B16 melanoma in vitro and the growth of B16-derived tumor in vivo, accompanied with the activation of natural killer (NK) cells. IFN-β cell therapy did not show any systemic side-effects concerning hepatic dysfunction and bone marrow suppression.Conclusion: IFN-β cell therapy could be a candidate as a novel cancer treatment.

Peptide Substrates for Rho-Associated Kinase 2 (Rho-Kinase 2/ROCK2)

Peptide substrates sensitive for a certain protein kinase could be important for new-drug development and to understand the mechanism of diseases. Rho-associated kinase (Rho-kinase/ROCK) is a serine/threonine kinase, and plays an important part in cardiovascular disease, migration and invasion of tumor cells, and in neurological disorders. The purpose of this study was to find substrates with high affinity and sensitivity for ROCK2. We synthesized 136 peptide substrates from protein substrates for ROCK2 with different lengths and charged peptides. Incorporation of 32P [counts per minute (CPM)] for each peptide substrate was determined by the radiolabel assay using [γ-32P]ATP. When the top five peptide substrates showing high CPMs (R4, R22, R133, R134, and R135) were phosphorylated by other enzymes (PKA, PKCα, and ERK1), R22, R133, and R135 displayed the highest CPM level for ROCK2 compared with other enzymes, whereas R4 and R134 showed similar CPM levels for ROCK2 and PKCα. We hypothesize that R22, R133, and R135 can be useful peptide substrates for ROCK2

RhoD Inhibits RhoC-ROCK-Dependent Cell Contraction via PAK6.

RhoA-mediated regulation of myosin-II activity in the actin cortex controls the ability of cells to contract and bleb during a variety of cellular processes, including cell migration and division. Cell contraction and blebbing also frequently occur as part of the cytopathic effect seen during many different viral infections. We now demonstrate that the vaccinia virus protein F11, which localizes to the plasma membrane, is required for ROCK-mediated cell contraction from 2 hr post infection. Curiously, F11-induced cell contraction is dependent on RhoC and not RhoA signaling to ROCK. Moreover, RhoC-driven cell contraction depends on the upstream inhibition of RhoD signaling by F11. This inhibition prevents RhoD from regulating its downstream effector Pak6, alleviating the suppression of RhoC by the kinase. Our observations with vaccinia have now demonstrated that RhoD recruits Pak6 to the plasma membrane to antagonize RhoC signaling during cell contraction and blebbing

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation